Posterior Reversible Leukoencephalopathy Syndrome in a Patient after Acute COVID-19 Infection.
Ketino KobaidzeYoo Mee ShinMariam JaparidzeIoannis KarakisXin Cynthia WuPublished in: Case reports in neurological medicine (2021)
The SARS-CoV-2 infection affects numerous organs, including the central nervous system. The neuroinvasive abilities and neuroinflammation may lead to short- and long-term neurological manifestations. Among neurological disorders associated with SARS-CoV-2 infection, posterior reversible encephalopathy syndrome (PRES) has been described in a few case-based observational studies during the acute phase of COVID-19 hospitalization. We present a case of a patient who developed seizures and PRES after recovering from an acute severe COVID-19 infection. A 90-year-old African American female with multiple comorbidities and a severe COVID-19 infection was discharged home in stable condition after two weeks of hospitalization. A week later, she developed new-onset generalized tonic-clonic seizures requiring readmission to the hospital. The patient's clinical course and brain imaging supported PRES. Her mentation returned to baseline with supportive care and anticonvulsant treatment. Follow-up brain MRI four months later demonstrated resolution of FLAIR signal abnormalities confirming PRES. SARS-CoV-2 insult on the cerebrovascular endothelial cells likely continued and despite the clinical recovery eventually resulted in PRES. We believe that this is the first case describing the presentation of PRES after recovery from severe acute COVID-19 infection.
Keyphrases
- case report
- sars cov
- african american
- respiratory syndrome coronavirus
- healthcare
- endothelial cells
- cerebral ischemia
- early onset
- coronavirus disease
- traumatic brain injury
- white matter
- high resolution
- drug induced
- computed tomography
- resting state
- multiple sclerosis
- emergency department
- randomized controlled trial
- brain injury
- contrast enhanced
- pain management
- chronic pain
- preterm birth
- electronic health record
- vascular endothelial growth factor
- mechanical ventilation
- adverse drug